P450 oxidoreductase (POR) deficiency is an autosomal recessive disorder of steroidogenesis with multiple clinical manifestations. POR is the electron donor for all microsomal P450 enzymes, including the three steroidogenic enzymes P450c17 (17α-hydroxylase/17,20-lyase), P450c21 (21-hydroxylase), and P450aro (aromatase). Since the first description of POR mutations in 2004, about 50 patients have been reported. Serum steroid profiles indicate partial deficiencies in 21-hydroxylase, 17α-hydroxylase and 17,20-lyase. The 17-OH progesterone levels are elevated, as in 21-hydroxylase deficiency, while androgen levels are low; cortisol may be normal but is poorly responsive to adrenocorticotropic hormone. Most patients also have associated skeletal malfor- mations (craniosynostosis, radio-ulnar synostosis, midface hypoplasia, bowed femora) termed Antley-Bixler syndrome. Antley-Bixler syndrome with normal steroidogenesis is caused by autosomal dominant gain-of-function mutations in fibroblast growth factor receptor 2. Males with POR deficiency are often undervirilized, while females can be virilized. The prognosis for patients with POR deficiency appears to depend on the severity of the bony malformations and their timely treatment. The potential impact of POR mutations on drug metabolism by other hepatic P450 enzymes requires further investigation. Given the varied physical and biochemical phenotype of POR deficiency and the risk of adrenal insufficiency, clinicians should be alert to this potential diagnosis.

Keywords:
Adrenal, steroidogenesis, Craniosynostosis, Antley-Bixler syndrome, Ambiguous genitalia, FGFR2 mutations, Adrenal steroidogenesis
1.
Miller WL: Congenital lipoid adrenal hyperplasia: the human gene knockout for the steroidogenic acute regulatory protein. J Mol Endocrinol 1997;19:227–240.
2.
Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonça BB, Fujieda K, Miller WL: Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004;36:228–230.
3.
Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, Borucka-Mankiewicz M, Hauffa BP, Malunowicz EM, Stewart PM, Shackleton CH: Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004;363:2128–2135.
4.
Adachi M, Tachibana K, Asakura Y, Yamamoto T, Hanaki K, Oka A: Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am J Med Genet A 2004;128:333–339.
5.
Miller WL: P450 oxidoreductase deficiency: a new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab 2004;15:311–315.
6.
Miller WL: Minireview: regulation of steroidogenesis by electron transfer. Endocrinology 2005;146:2544–2550.
7.
Scott RR, Gomes LG, Huang N, Van Vliet G, Miller WL: Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007;92:2318–2322.
8.
Yamazaki H, Johnson WW, Ueng YF, Shimada T, Guengerich FP: Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5. J Biol Chem 1996;271:27438–27444.
9.
Auchus RJ, Lee TC, Miller WL: Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 1998;273:3158–3165.
10.
Geller DH, Auchus RJ, Miller WL: P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Mol Endocrinol 1999;13:167– 175.
11.
Guengerich FP, Johnson WW: Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems. Biochemistry 1997;36:14741–14750.
12.
Yanagibashi K, Hall PF: Role of electron transport in the regulation of the lyase activity of C21 side-chain cleavage P-450 from porcine adrenal and testicular microsomes. J Biol Chem 1986;261:8429–8433.
13.
Lin D, Black SM, Nagahama Y, Miller WL: Steroid 17α-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase. Endocrinology 1993;132:2498–2506.
14.
Peterson RE, Imperato-McGinley J, Gautier T, Shackleton C: Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. N Engl J Med 1985;313:1182–1191.
15.
Malunowicz E, Romer TE, Szarras-Czapnik M, Mielniczuk Z, Gajewska D: Combined deficiency of 17α-hydroxylase and 21-hydroxylase in an 8 years old girl. Endokrynol Pol 1987;38:117–124.
16.
Augarten A, Pariente C, Gazit E, Chayen R, Goldfarb H, Sack J: Ambiguous genitalia due to partial activity of cytochromes P450c17 and P450c21. J Steroid Biochem Mol Biol 1992;41:37–41.
17.
Leiberman E, Hershkovitz E, Lauber-Biason A, Phillip M, Zachmann M: Subnormal cortisol response to adrenocorticotropin in isolated partial 17,20-lyase deficiency. J Pediatr Endocrinol Metab 1997;10:387–390.
18.
Adachi M, Tachibana K, Asakura Y, Suwa S, Nishimura G: A male patient presenting with major clinical symptoms of glucocorticoid deficiency and skeletal dysplasia, showing a steroid pattern compatible with 17α-hydroxylase/17,20-lyase deficiency, but without obvious CYP17 gene mutations. Endocr J 1999;46:285–292.
19.
Reardon W, Smith A, Honour JW, Hindmarsh P, Das D, Rumsby G, Nelson I, Malcolm S, Ades L, Sillence D, Kumar D, DeLozier-Blanchet C, McKee S, Kelly T, McKeehan WL, Baraitser M, Winter RM: Evidence for digenic inheritance in some cases of Antley-Bixler syndrome? J Med Genet 2000;37:26–32.
20.
Kelley RI, Kratz LE, Glaser RL, Netzloff ML, Wolf LM, Jabs EW: Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. Am J Med Genet 2002;110:95–102.
21.
Miller WL: Congenital adrenal hyperplasia. N Engl J Med 1987;317:1413–1415.
22.
Otto DM, Henderson CJ, Carrie D, Davey M, Gundersen TE, Blomhoff R, Adams RH, Tickle C, Wolf CR: Identification of novel roles of the cytochrome P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 2003;23:6103–6116.
23.
Shen AL, O’Leary KA, Kasper CB: Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 2002;277:6536–6541.
24.
Gu J, Weng Y, Zhang QY, Cui H, Behr M, Wu L, Yang W, Zhang L, Ding X: Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003;278:25895–25901.
25.
Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, Wolf CR: Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003;278:13480–13486.
26.
Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, Miller WL: Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005;76:729–749.
27.
Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, Okuyama T, Nakai H, Soneda S, Tachibana K, Matsuo N, Sato S, Homma K, Nishimura G, Hasegawa T, Ogata T: Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 2005;90:414–426.
28.
Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res 2006;59:276–280.
29.
Homma K, Hasegawa T, Nagai T, Adachi M, Horikawa R, Fujiwara I, Tajima T, Takeda R, Fukami M, Ogata T: Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J Clin Endocrinol Metab 2006;91:2643–2649.
30.
Antley R, Bixler D: Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser 1975;11:397–401.
31.
DeLozier CD, Antley RM, Williams R, Green N, Heller RM, Bixler D, Engel E: The syndrome of multisynostotic osteodysgenesis with long-bone fractures. Am J Med Genet 1980;7:391–403.
32.
Crisponi G, Porcu C, Piu ME: Antley-Bixler syndrome: case report and review of the literature. Clin Dysmorphol 1997;6:61–68.
33.
Bottero L, Cinalli G, Labrune P, Lajeunie E, Renier D: Antley-Bixler syndrome. Description of two new cases and a review of the literature. Childs Nerv Syst 1997;13:275–280; discussion 281.
34.
Chun K, Siegel-Bartelt J, Chitayat D, Phillips J, Ray PN: FGFR2 mutation associated with clinical manifestations consistent with Antley-Bixler syndrome. Am J Med Genet 1998;77:219–224.
35.
Gorlin RJ: Patient described by Chun et al. may not present Antley-Bixler syndrome. Am J Med Genet 1999;83:64.
36.
Gripp KW, Stolle CA, McDonald-McGinn DM, Markowitz RI, Bartlett SP, Katowitz JA, Muenke M, Zackai EH: Phenotype of the fibroblast growth factor receptor 2 Ser351Cys mutation: Pfeiffer syndrome type III. Am J Med Genet 1998;78:356–360.
37.
Schinzel A, Savoldelli G, Briner J, Sigg P, Massini C: Antley-Bixler syndrome in sisters: a term newborn and a prenatally diagnosed fetus. Am J Med Genet 1983;14:139–147.
38.
LeHeup BP, Masutti JP, Droulle P, Tisserand J: The Antley-Bixler syndrome: report of two familial cases with severe renal and anal anomalies. Eur J Pediatr 1995;154:130–133.
39.
Feigin E, Udassin R, Seror D, Szold A, Ben Neriah Z, Glick B: Antley-Bixler syndrome and esophageal atresia in a patient with trisomy 21. Clin Genet 1995;47:53–55.
40.
Pulleyn LJ, Reardon W, Wilkes D, Rutland P, Jones BM, Hayward R, Hall CM, Brueton L, Chun N, Lammer E, Malcolm S, Winter RM: Spectrum of craniosynostosis phenotypes associated with novel mutations at the fibroblast growth factor receptor 2 locus. Eur J Hum Genet 1996;4:283–291.
41.
Schaefer F, Anderson C, Can B, Say B: Novel mutation in the FGFR2 gene at the same codon as the Crouzon syndrome mutations in a severe Pfeiffer syndrome type 2 case. Am J Med Genet 1998;75:252–255.
42.
Cohen MM Jr: The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet A 2006;140:2646–2706.
43.
Muenke M, Schell U, Hehr A, Robin NH, Losken HW, Schinzel A, Pulleyn LJ, Rutland P, Reardon W, Malcolm S, et al: A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nat Genet 1994;8:269–274.
44.
Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, Malcolm S: Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 1994;8:98–103.
45.
Rutland P, Pulleyn LJ, Reardon W, Baraitser M, Hayward R, Jones B, Malcolm S, Winter RM, Oldridge M, Slaney SF, et al: Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nat Genet 1995;9:173–176.
46.
Park WJ, Meyers GA, Li X, Theda C, Day D, Oriow SJ, Jones MC, Jabs EW: Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Hum Mol Genet 1995;4:1229–1233.
47.
Lajeunie E, Ma HW, Bonaventure J, Munnich A, Le Merrer M, Renier D: FGFR2 mutations in Pfeiffer syndrome. Nat Genet 1995;9:108.
48.
Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA: Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996;22:336–340.
49.
Aleck KA, Bartley DL: Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997;72:253–256.
50.
Lee BE, Feinberg M, Abraham JJ, Murthy AR: Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J 1992;11:1062–1064.
51.
Shackleton C, Marcos J, Arlt W, Hauffa BP: Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. Am J Med Genet A 2004;129:105–112.
52.
Gofflot F, Hars C, Illien F, Chevy F, Wolf C, Picard JJ, Roux C: Molecular mechanisms underlying limb anomalies associated with cholesterol deficiency during gestation: implications of Hedgehog signaling. Hum Mol Genet 2003;12:1187–1198.
53.
Geller DH, Auchus RJ, Mendonca BB, Miller WL: The genetic and functional basis of isolated 17,20-lyase deficiency. Nat Genet 1997;17:201–205.
54.
Auchus RJ, Miller WL: Molecular modeling of human P450c17 (17α-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol Endocrinol 1999;13:1169–1182.
55.
Krone N, Dhir V, Ivison HE, Arlt W: Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clin Endocrinol (Oxf) 2007;66:162–172.
56.
Auchus RJ: The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004;15:432–438.
57.
Meinhardt U, Mullis PE: The aromatase cytochrome P-450 and its clinical impact. Horm Res 2002;57:145–152.
58.
Wilson JD, Auchus RJ, Leihy MW, Guryev OL, Estabrook RW, Osborn SM, Shaw G, Renfree MB: 5α-Androstane-3α,17β-diol is formed in tammar wallaby pouch young testes by a pathway involving 5α-pregnane-3α,17α-diol-20-one as a key intermediate. Endocrinology 2003;144:575–580.
59.
Gupta MK, Guryev OL, Auchus RJ: 5α-Reduced C21 steroids are substrates for human cytochrome P450c17. Arch Biochem Biophys 2003;418:151–160.
60.
Jacobson RL, Dignan PS, Miodovnik M, Siddiqi TA: Antley-Bixler syndrome. J Ultrasound Med 1992;11:161–164.
61.
Antonarakis SE: Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998;11:1–3.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.